Roche said group sales increased 5% to CHF25bn in the six months to June 30, slightly ahead of expectations. Net income rose by 3% at constant currencies to CHF5.5bn. Pharmaceutical sales were up by 4% to CHF19.5bn, driven by oncology and immunology drugs.
Tecentriq (atezolizumab), which was approved by the FDA in May 2016 for bladder cancer, had revenues of CHF19m "in a...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
